Merck KGaA makes $600M bet to boost manufacturing for viral vectors
Merck KGaA announced Wednesday that it is acquiring Mirus Bio, a startup that develops transfection reagents for viral cell and gene therapies, for $600 million. “Combining Mirus Bio’s leading technology with our bioprocessing …